Faruqi and Faruqui, LLP Logo
Share this page

United Therapeutics Corporation (UTHR)

NasdaqGS:UTHR

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In United Therapeutics Corporation To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at United Therapeutics Corporation (“United Therapeutics” or the “Company”) (NasdaqGS:UTHR).

The investigation focuses on whether the Company and its executives violated federal securities laws. On July 27, 2017, the Company reported its second quarter 2017 financial results in which it revealed an accrual of $210 million relating to settlement negotiations with the U.S. Department of Justice (“DOJ”). Specifically, the negotiations regard a DOJ investigation into whether the Company violated the Federal Anti-Kickback Statute and the Federal False Claims Act by supporting certain 501(c)(3) organizations that provide financial assistance to patients.

Following this disclosure, the Company’s share price declined, causing harm to investors.

If you invested in United Therapeutics stock or options and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    United Therapeutics Corporation (UTHR)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 07/27/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.